EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Relationship between factor VIII mutation type and inhibitor development in a cohort of previously untreated patients treated with recombinant factor VIII (RecombinateTM)



Relationship between factor VIII mutation type and inhibitor development in a cohort of previously untreated patients treated with recombinant factor VIII (RecombinateTM)



Thrombosis and Haemostasis 83(6): 844-848



A cohort of 79 previously untreated patients (PUPs) with moderate-severe haemophilia A (baseline Factor VIII ltoreq2%) were enrolled in a study to evaluate the safety, efficacy and immunogenicity of recombinant factor VIII (r-FVIII, RecombinateTM). Blood samples were obtained retrospectively from a total 55 PUPs who were investigated for the spectrum of FVIII gene mutations responsible for their haemophilia. FVIII gene inversion mutations were found in 27 (49%) patients.

(PDF emailed within 1 workday: $29.90)

Accession: 011274729

Download citation: RISBibTeXText



Related references

Relationship between factor VIII mutation type and inhibitor development in a cohort of previously untreated patients treated with recombinant factor VIII (Recombinate). Recombinate PUP Study Group. Thrombosis and Haemostasis 83(6): 844-848, 2000

Measurement of anti-factor VIII IgG, IgG4 and IgM alloantibodies in previously untreated hemophilia A patients treated with recombinant factor VIII. International Journal of Hematology 62(1): 35-43, 1995

Measurement of anti-factor VIII IgG, IgG4 and IgM alloantibodies in previously untreated hemophilia A patients treated with recombinant factor VIII. Kogenate Japanese Clinical Study Group. International Journal of Hematology 62(1): 35-43, 1995

Initial studies of genetic factors influencing inhibitor development in previously untreated patients with hemophilia treated with recombinant factor VIII. Blood 86(10 SUPPL 1): 610A, 1995

Incidence of factor VIII inhibitor development in previously untreated hemophilia A patients after exposure to a double viral inactivated factor VIII concentrate. Annals of Hematology 78(SUPPL 1): A10, 1999

Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review. Journal of Thrombosis and Haemostasis 8(6): 1256-1265, 2010

Utilization of previously treated patients (PTPs), noninfected patients (NIPs), and previously untreated patients (PUPs) in the evaluation of new factor VIII and factor IX concentrates. Recommendation of the Scientific Subcommittee on Factor VIII and Factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thrombosis and Haemostasis 81(3): 462-462, 1999

Cost analysis of plasma-derived factor VIII/von Willebrand factor vs recombinant factor VIII for treatment of previously untreated patients with severe hemophilia A in the United States. Journal of Medical Economics: 1-16, 2018

Factor VIII inhibitors development following introduction of B-domain-deleted recombinant factor VIII in four hemophilia A previously treated patients. Journal of Thrombosis and Haemostasis 1(11): 2450-2451, 2003

Hemophilic patients with an inhibitor to factor VIII treated with high dose factor VIII concentrate. Results of a collaborative study for the evaluation of factor VIII inhibitor titer, recovery and half life of infused factor VIII. Nouvelle Revue Francaise D'hematologie 28(2): 85-89, 1986

Inhibitor development in prospective clinical trials with recombinant factor VIII preparations in previously untreated patients. Vox Sanguinis 77 Suppl 1: 9-9, 1999

First and second generation recombinant factor VIII concentrates in previously untreated patients: recovery, safety, efficacy, and inhibitor development. Seminars in Thrombosis and Hemostasis 28(3): 273-276, 2002

Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood 107(1): 46-51, 2005

Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood 107(1): 46-51, 2006

Rates of Inhibitor development in previously untreated patients with severe hemophilia A treated with plasma-derived or recombinant factor VIII: no proof of difference or proof of no difference?. Seminars in Thrombosis and Hemostasis 40(2): 269-270, 2014